Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia

Co-Diagnostics (Co-Dx; Salt Lake City, UT, USA) has signed an agreement for CoSara Diagnostics Pvt. Ltd., its Indian joint venture with Ambalal Sarabhai Enterprises Limited (Ahmedabad, India), to extend commercial and distribution rights to Bangladesh, Pakistan, Nepal, and Sri Lanka.

The company estimates this expansion lifts CoSara’s addressable South Asia market to USD 13 billion, based on internal analyses and third-party data. The broadened territory is intended to support commercialization of the CoSara PCR Pro point-of-care instrument and tests and the SARAGENE product line. All activities remain subject to applicable regulatory approvals in each country.

Image: The Co-Dx PCR platform brings lab-quality PCR testing to point-of-care settings (Photo courtesy of Co-Dx)

Co-Diagnostics develops technologies for tests that detect and analyze nucleic acid molecules. Within its portfolio, the Co‑Dx PCR platform comprises the PCR Home, PCR Pro, a mobile app, and associated assays. CoSara’s plans emphasize deploying the PCR Pro system in point‑of‑care environments for molecular testing aligned to regional needs.

The Co‑Dx PCR platform, including the PCR Home, PCR Pro, mobile app, and all associated tests, is currently under review by the U.S. Food and Drug Administration (FDA) and other regulatory bodies and is not yet available for sale. As it enters these markets, CoSara is evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners. A virtual distributor information session is planned for the second quarter of 2026, followed by an in‑person distributor meeting and training later in the summer.

"South Asia represents a large and rapidly growing market for molecular diagnostics, with significant need for easily accessible, non-invasive, quick and reliable testing solutions. Expanding our territory allows us to begin building relationships with regional partners and positions us to support the future commercialization of the point-of-care PCR platform across these markets, increasing access to molecular tests for tuberculosis, HPV, and upper respiratory infections." said Mohal Sarabhai, CEO, CoSara Diagnostics Pvt. Ltd.

"This expansion reflects our broader strategy of establishing regional infrastructure ahead of product commercialization. By building local manufacturing and distribution capabilities in key regions, including the United States, South Asia, and the Middle East and North Africa, we are positioning Co-Dx to support scalable, global deployment of our PCR point-of-care platform and drive long-term growth." said Dwight Egan, CEO, Co-Diagnostics, Inc.

Related Links
Co-Diagnostics, Inc.
CoSara Diagnostics Pvt. Ltd.
Ambalal Sarabhai Enterprises Limited